Exelixis | EXEL - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
Amgen USD 541M 1000K 2026-06
AstraZeneca USD 1.55B 44K 2026-06
Bayer EUR 982.42M 0 2026-06
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cytokinetics USD 124.43M 2.17M 2026-03
Eisai JPY 282.46M 345K 2026-06
Eli Lilly USD 943.5M 3.33M 2026-03
Exelixis USD 248.88M 4.82M 2026-06
Genmab DKK 61.44M 181K 2026-06
Glaxosmithkline GBP 4.05B 20.6M 2026-03
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
MacroGenics USD 63.56M 241K 2026-03
Merck USD 2.47B 4.93M 2026-03
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Novartis USD 1.9B 7.38M 2026-06
Pfizer USD 5.7B 0 2026-06
Puma Biotechnology USD 5K 0 2024-06
Sanofi EUR 1.2B 16.88M 2026-03
Takeda JPY 1.58B 460K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Xencor USD 74.33M 265K 2026-06